来自临床和临床前研究的大量证据表明二甲双胍的使用与降低癌症风险之间存在关联。然而,二甲双胍对癌症的影响尚未进行文献计量学分析.本研究的目的是探索二甲双胍对癌症的潜在影响,并对与二甲双胍对癌症的使用相关的研究热点进行全面评估。使用各种工具,如AdobeIllustratorCC2018,VOSviewer,CiteSpace,和R包“文献计量。“2013年至2023年的平均年度出版物为372。在期刊和共同引用期刊方面,共1064种期刊发表1958年论文,Oncotarget发表的论文数量最多(n=153,7.81%),而癌症研究(共引用=5,125)是最常被引用的期刊。共有25,665位作者参与了二甲双胍用于癌症的研究。二甲双胍在各种类型的癌症中显示出改善的结果,包括乳腺癌(BC),肺癌(LC),结直肠癌(CRC),前列腺癌(PC),还有胰腺癌.本文献计量分析回顾了目前有关二甲双胍用于癌症的临床数据的文献,并描述了临床前证据,说明了二甲双胍直接或间接用于各种癌症的潜在机制。
There is substantial evidence from clinical and preclinical studies suggesting an association between metformin use and a reduced risk of cancer. However, the effects of metformin use on
cancers have not yet been subjected to bibliometric analysis. The goal of this study was to explore the potential effects of metformin use on
cancers and to conduct a comprehensive assessment of research hotspots related to the use of metformin on
cancers. The results of the literature analysis were visualized using various tools such as Adobe Illustrator CC 2018, VOSviewer, CiteSpace, and the R package \"bibliometric.\" The average annual publications from 2013 to 2023 was 372. In terms of journals and co-cited journals, a total of 1,064 journals published 1958 papers, and Oncotarget published the highest number of papers (n = 153, 7.81%), while Cancer Research (Co-citation = 5,125) was the most frequently cited journal. A total of 25,665 authors participated in the research on metformin use on
cancers. Metformin has demonstrated improved outcomes in various types of cancer, including breast cancer (BC), lung cancer (LC), colorectal cancer (CRC), prostate cancer (PC), and pancreatic cancer. This bibliometric analysis reviews the current literature on the clinical data on metformin use on
cancers and describes the preclinical evidence illustrating the potential mechanisms of metformin use on various cancers directly or indirectly.